EUVIMEDEUVIMED entdecken
Crossref

Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy

Teng Yang, Ze Dong iD, Rong Du, Yiqing Wang, Lu Liu, Yangyang Xue, Xi Zhang, Yonggang Liao, Jianhua Gan iD, Xiaoxuan Yu, Yue Huang, Cai-Guang Yang iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c00566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Teng Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, C…. Hauptthemen laut MEDLINE: Alpha-Ketoglutarate-Dependent Dioxygenase FTO, Leukemia, Myeloid, Acute, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hangzhou Institute for Advanced Study, University of the Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N6-Methyladenosine (m6A), the most prevalent mRNA modification, undergoes dynamic regulation mediated by the demethylase fat mass and obesity-associated protein (FTO), which is aberrantly overexpressed in acute myeloid leukemia (AML) and drives leukemogenesis. Based on the structure-guided optimization of our previously reported FTO inhibitor Dac85 and fluorescein, we developed Dac590, a tricyclic benzoic acid derivative with potent FTO inhibitory activity and improved pharmacokinetic properties. Dac590 exerts a robust antiproliferative effect on AML cells by suppressing oncogenic FTO signaling. Oral administration of Dac590 significantly inhibited xenograft tumor growth and prolonged survival in AML mouse models with no observed toxicity. Notably, Dac590 synergized with decitabine to enhance DNA hypomethylation and further improve the survival rates. Our study identifies Dac590 as a potent orally bioavailable FTO inhibitor and demonstrates a combinatorial strategy through dual epigenetic modulations for enhanced AML therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alpha-Ketoglutarate-Dependent Dioxygenase FTOLeukemia, Myeloid, AcuteAntineoplastic AgentsEnzyme InhibitorsAnimalsHumansMiceAdministration, OralCell Line, TumorCell ProliferationStructure-Activity RelationshipXenograft Model Antitumor AssaysBiological AvailabilityMaleDNA Methylation

Substanzen

Alpha-Ketoglutarate-Dependent Dioxygenase FTOFTO protein, humanAntineoplastic AgentsEnzyme Inhibitors

Autor:innen und Institutionen

  • School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
  • University of the Chinese Academy of Sciences, Beijing 100049, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.
  • Rname Pharmaceutical Technology (Shanghai) Co., LTD., Shanghai 430048, China.

ORCID-Profile: Ze Dong, Jianhua Gan, Cai-Guang Yang

Förderung

  • National Natural Science Foundation of China
  • Hangzhou Institute for Advanced Study, University of the Chinese Academy of Sciences

Zitieren

APA

Yang, T., Dong, Z., Du, R., Wang, Y., Liu, L., Xue, Y., Zhang, X., Liao, Y., Gan, J., Yu, X., Huang, Y., & Yang, C. G. (2025). Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00566

Vancouver

Yang T, Dong Z, Du R, Wang Y, Liu L, Xue Y, et al. Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00566

BibTeX
@article{Yang2025,
  author = {Yang, Teng and Dong, Ze and Du, Rong and Wang, Yiqing and Liu, Lu and Xue, Yangyang and Zhang, Xi and Liao, Yonggang and Gan, Jianhua and Yu, Xiaoxuan and Huang, Yue and Yang, Cai-Guang},
  title = {Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c00566}
}
Kostenlos starten →